Publication details

TYSABRI – nový management rizik

Title in English TYSABRI – new management of risk factors


Year of publication 2017
Type Article in Periodical
Magazine / Source Neurologie pro praxi
MU Faculty or unit

Faculty of Medicine

Field Neurology, neurosurgery, neurosciences
Keywords natalizumab; monoclonal antibodies; multiple sclerosis; progressive multifocal leukoencephalopathy
Description Natalizumab belongs to monoclonal antibodies. This is a high- efficacy drug, which substantially reduces the activity and leads to long-term stabilization of multiple sclerosis. However, the therapy is associated with a risk of developing progressive multifocal leukoencephalopathy (PML) in patients infected with the John Cunningham Virus. Standardized high-quality monitoring procedures, clinical assessments, magnetic resonance imaging monitoring and use of biomarkers enable risk stratification. Early detection of disease in asymptomatic stage substantially improves survival and reduce the functional outcomes.

You are running an old browser version. We recommend updating your browser to its latest version.

More info